Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ecaWCfbwoceVmmAZLpCn

  ADVERTISEMENT  
December 10, 2012News for the transfusion medicine and cellular therapy community

  Top Story 
 
  • Girl with leukemia in remission after gene treatment
    A girl with acute lymphoblastic leukemia experienced remission after being treated with an experimental therapy that used a disabled form of HIV to genetically reprogram her immune system to fight the cancer. The girl is the first child to undergo the treatment, and some experts said it could someday serve in place of bone marrow transplants. Novartis has expressed interest in the treatment and has pledged $20 million to establish a research center for it at the University of Pennsylvania. The New York Times (tiered subscription model) (12/9) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
Quotient is on a roll with new FDA approvals & GPO contracts
More good news from Quotient! Not only do we have FDA-approved Reagent Red Blood Cells products, but also just approved Rare Antisera, including Anti-s and Anti-Wra. We also have new 3-yr agreements with Premier Inc. and the General Services Administration. Great products and value from the one manufacturer focused on manual testing. Contact us today.

  Science & Health 
  • Lower risk of major bleeding seen with rivaroxaban
    An analysis found that oral rivaroxaban was associated with fewer bleeding incidents in patients with symptomatic venous thromboembolism compared with standard therapy. The association was the strongest in older patients and those with moderate renal impairment. HemOnc Today (12/9) LinkedInFacebookTwitterEmail this Story
  • Blood thinner apixaban achieves main goal in study
    The anti-clotting drug apixaban met the primary goal in a trial by significantly reducing recurrence of blood clots in patients with previously treated venous thromboembolism. Deaths from all causes were lower and the treatment was not associated with an increase in major bleeding events, according to the study of 2,486 patients published in the New England Journal of Medicine. Reuters (12/8) LinkedInFacebookTwitterEmail this Story
  • Double cord blood transplant shows no survival advantage in children
    Children with hematologic malignancies who underwent hematopoietic stem cell transplantation with double units of umbilical cord blood didn't have better outcomes than those who got single units, a study found. Disease-free survival and relapse rates were comparable in both groups, but severe graft-versus-host disease was more prevalent in the double-unit group, according to the study of 224 children treated at 38 centers. HemOnc Today (12/9) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
Clinical Research: Understanding the Methodology Toolbox
Clinical Research: Understanding the Methodology Toolbox compiles articles of evidence-based research for use as an educational resource for those involved in clinical research, healthcare professionals and trainees in transfusion medicine and other medical specialties. Now in the AABB Marketplace.

  Hot Topics 

Top five news stories selected by AABB SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Emerging Trends 
  • Researchers develop brain cells from urine
    Scientists have developed a method for converting cells flushed through urine into neural progenitor cells, the precursors of brain cells. Instead of using retroviruses to insert pluripotency genes into the cells, researchers employed vectors that do not integrate with the cellular genome. Experiments on rat brains showed the engineered cells did not create tumors, according to the study published in Nature Methods. Precursor cells could allow for quicker development of personalized cells. Nature (12/9) LinkedInFacebookTwitterEmail this Story
  Industry News & Practice 
  Government & Regulatory 
  • FDA to hold hearing on contamination of skin prep wipes
    Reducing bacterial contamination of alcohol wipes and other skin prep products will be the subject of an FDA hearing Wednesday and Thursday. "We think a sterile wipe should be used in health care. I'm thrilled that FDA is getting people to the table," said nurse and epidemiologist Susan Dolan of Children's Hospital Colorado in Aurora. NBC News/Vitals blog (12/5) LinkedInFacebookTwitterEmail this Story
  Association News 
  • Upcoming audioconference to address massive transfusion protocol
    A Wednesday AABB audioconference titled "1:1:1 Ratio of Massive Transfusion" will examine the use of a massive transfusion protocol, or MTP, for patients suffering from traumatic injuries. The program will address when an MTP should be initiated, how much blood should be available and whether a 1:1:1 ratio of blood products is appropriate. Registration materials are available online. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
West Coast Account ManagerMacopharma USAUS - Nationwide
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Click here to view more job listings.

  SmartQuote 
Alas for those that never sing, But die with all their music in them."
--Oliver Wendell Holmes Sr.,
American physician, writer and poet


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information